Form 4: Pfizer Director Acquires Phantom Stock Units

Pfizer Director Joseph Echevarria acquired 1,710.429 phantom stock units as deferred compensation, increasing his beneficial ownership to 153,398.145 units.

Summary

• Joseph Echevarria, a Director of Pfizer Inc. (PFE), acquired 1,710.429 phantom stock units.
• The transaction date for this acquisition was March 27, 2026.
• Each phantom stock unit represents one phantom share of common stock and was valued at $27.04.
• These units are part of deferred director's compensation, including dividend equivalents, and will be settled in cash or common stock at the director's election upon retirement from the Board.
• Following this transaction, Joseph Echevarria beneficially owns a total of 153,398.145 phantom stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It is a routine compensation transaction for a director, which is a standard practice and does not indicate any significant positive or negative operational or financial developments for Pfizer.

Positives

• The acquisition of phantom stock units aligns the director's long-term interests with those of shareholders, as the value of these units is tied to the company's common stock performance.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on an insider transaction.

Industry Context

StockSavvy.ai notes that the grant of phantom stock units as deferred compensation is a common practice among large publicly traded companies. This mechanism is widely used to incentivize and retain directors by aligning their financial interests with the long-term performance of the company's stock, similar to compensation structures seen at peer pharmaceutical companies.

Comparison to Industry Standards

• The use of phantom stock units for director compensation is a standard practice across the pharmaceutical industry and other large-cap sectors, comparable to companies like Johnson & Johnson or Merck & Co. This method provides equity-linked compensation without immediate share issuance, often tied to retirement or service milestones.
• The specific valuation and number of units granted are consistent with typical deferred compensation packages for non-executive directors at companies of Pfizer's size and market capitalization, reflecting a common approach to governance and incentive alignment.

Corporate Governance

Related Party Transactions

• The acquisition of phantom stock units by Joseph Echevarria, a director, constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The transaction aligns the director's financial interests with long-term shareholder value, potentially fostering more shareholder-centric decision-making.
• Employees: No direct impact on employees is indicated by this specific filing.

Key Dates

Keywords

Pfizer, PFE, Form 4, Insider Transaction, Director Compensation, Phantom Stock Units, Joseph Echevarria, Deferred Compensation